Related Experiment Videos
Immunophenotyping of acute leukemias using paraffin-embedded tissue sections
A S Kurec1, V E Cruz, D Barrett
1Department of Pathology, State University of New York Health Science Center, Syracuse 13210.
American Journal of Clinical Pathology
|April 1, 1990
Summary
Immunohistochemistry using specific antibodies on bone marrow sections aids in diagnosing acute leukemias. This method effectively differentiates acute myeloid leukemia (AML) subtypes from acute lymphoid leukemia (ALL).
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Accurate classification of acute leukemias is crucial for effective treatment.
- Distinguishing between acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) is essential.
- Immunophenotyping aids in subtyping leukemias.
Purpose of the Study:
- To evaluate the utility of a panel of antibodies for diagnosing and immunophenotypically classifying acute leukemias.
- To determine the diagnostic value of myeloid-associated antibodies in paraffin-embedded bone marrow sections.
Main Methods:
- Examined 55 bone marrow particle sections from patients with ALL and AML.
- Utilized alkaline phosphatase-anti-alkaline phosphatase (APAAP) technique with monoclonal and polyclonal antibodies.
- Classified cases using the French-American-British (FAB) Co-operative Group criteria and flow cytometry for ALL.
Main Results:
- Myeloid-associated antibodies reacted with 95% of M2, M3, M4, and M5-AML cases, but not ALL, M1-AML, or M6-AML.
- Anti-glycophorin C identified M6-AML, and anti-CD3 labeled T-cell ALL.
- No antibody specifically identified B-cell ALL.
Conclusions:
- A selected antibody panel on bone marrow sections is valuable for diagnosing and immunophenotypically classifying acute leukemias.
- This immunohistochemical approach aids in differentiating AML subtypes.
- Further refinement may improve identification of all acute leukemia subtypes.